1. Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases
- Author
-
Nan Chen, Julie R. Nangia, Valentina Hoyos, Binu Liz Michael, Nicole Higashiyama, Mothaffar F. Rimawi, and Maryam Nemati Shafaee
- Subjects
Oncology ,medicine.medical_specialty ,Antibody-drug conjugate ,Central nervous system ,Article ,Breast cancer ,Trastuzumab ,Internal medicine ,HER2 ,medicine ,Adverse effect ,Dose Reduced ,skin and connective tissue diseases ,RC254-282 ,General Environmental Science ,Leptomeningeal metastases ,business.industry ,General Engineering ,Liver failure ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Metastatic breast cancer ,medicine.anatomical_structure ,General Earth and Planetary Sciences ,business ,medicine.drug - Abstract
Trastuzumab deruxtecan has been shown to have responses in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, the safety of this medication in patients with severe liver dysfunction and untreated or symptomatic central nervous system metastases is unknown. We describe a patient with metastatic HER2-positive breast cancer with liver failure and leptomeningeal metastases who was treated with dose-reduced trastuzumab deruxtecan. With treatment, the patient's hyperbilirubinemia resolved and she demonstrated a response on imaging. She was dose-escalated to full dose with minimal adverse events.
- Published
- 2020